The cancer diagnostics company has gone into a trading halt following an adverse decision on reimbursement of its US bladder tests.
Pole infrastructure software company is positive about the future even as 'additive' transaction revenue drops.
AJ Smith's contribution of as much as 22.7% of $2.2m fund raise requires shareholder approval.
The restructure at Building Products subsidiary Easysteel was revealed to union negotiators last week.
Outgoing CEO Kippenberger hails increasing revenue contribution from 'core' materials, minerals and protein markets.
The deal will create a Trans-Tasman business with forecast 2024 sales of A$400m.
While the offer was a premium on the recent shareprice the valuation was well below its A$455m peak in 2019.
Independent directors and experts Grant Samuels have both changed their views and believe Seven’s amended offer is now reasonable.
Forbar analysts cut earnings forecasts, despite predicting improved profits.
The NZX-listed medicinal cannabis firm went into voluntary administration late last month.